Thank you for subscribing!
Finfeed Archived Sep 11, 2019
The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.
Finfeed Archived Aug 28, 2019
Imagion Biosystems (ASX:IBX) CEO, Robert Proulx speaks to Finfeed's Jonathan Jackson about the company's important work in early stage cancer detection.
Next Investors Archived Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
Finfeed Archived Jul 25, 2019
Queenstown, the New Zealand extreme sport mecca, hosts the annual Bioshares Biotech Summit, gathering together some of the best long-standing and emerging biotech companies in the country to talk all things trials, tribulations and potential cures for cancer.
Get expert stock analysis direct in your inbox
Next Investors Archived Jul 25, 2019
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.
Finfeed Archived May 23, 2019
Drug delivery company Invion Limited (ASX:IVX) is leading the way in developing PhotosoftTM technology for the treatment of a range of cancers.
Next Investors Archived May 14, 2019
What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).
Finfeed Archived May 13, 2019
Shares in Genetic Technologies Ltd (ASX:GTG; NASDAQ:GENE) surged nearly 60% on Friday after the company announced two new ground-breaking cancer risk assessment tests had been completed and validated.
Finfeed Archived Mar 28, 2019
Genetic Technologies (ASX:GTG), a provider of world-leading genetic risk assessment test products,has announced the establishment of its Asian operations within the Hainan Resort Software Community (HRSC) Free Trade Zone.
Finfeed Archived Mar 21, 2019
Imugene Limited (ASX:IMU) has now received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy.
Finfeed Archived Mar 14, 2019
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced dosing of the first patient in a in 68 patient randomised Phase 2 HER-Vaxx cancer trial.
Finfeed Archived Mar 04, 2019
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on its KEYVaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
Finfeed Archived Feb 28, 2019
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.
Next Investors Archived Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.
Finfeed Archived Jan 29, 2019
Prescient Therapeutics (ASX:PTX) CEO Steven Yatomi-Clarke speaks with Finfeed about the latest results in the company's cancer treatment trials.
Finfeed Archived Dec 17, 2018
Imugene (ASX:IMU) has met all study endpoints and produced positive top-line results from its Phase 1b study of its HER-Vaxx gastric cancer vaccine.
Next Investors Archived Dec 17, 2018
Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.
Finfeed Archived Nov 28, 2018
Medical diagnostics pioneer, Rhythm Biosciences (ASX: RHY), has made some senior management changes, appointing Glenn Gilbert as its CEO, effective immediately.
Join Our Mailing List
